University of Kansas Cancer Center Post San Antonio Review
Genomic Signatures in Adjuvant Therapy of HR+ EBC: Should We Consider Abemaciclib x2 Years to ET in Very-High Risk Patients? Can Longer CDK4/6i Duration Prevent Late Relapses?
Comments 0
Login to view comments.
Click here to Login
